Batt K - Search Results

1

Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.

Cope S, Ayers D, Zhang J, Batt K, Jansen JP. Cope S, et al. Among authors: batt k. BMC Med Res Methodol. 2019 Sep 2;19(1):182. doi: 10.1186/s12874-019-0823-8. BMC Med Res Methodol. 2019. PMID: 31477025 Free PMC article.

2

The potential impact of CAR T-cell treatment delays on society.

Thornton Snider J, Brauer M, Kee R, Batt K, Karaca-Mandic P, Zhang J, Goldman DP. Thornton Snider J, et al. Among authors: batt k. Am J Manag Care. 2019 Aug;25(8):379-386. Am J Manag Care. 2019. PMID: 31419095 Free article.

3

Real-world resource use and costs of haemophilia A-related bleeding.

Shrestha A, Eldar-Lissai A, Hou N, Lakdawalla DN, Batt K. Shrestha A, et al. Among authors: batt k. Haemophilia. 2017 Jul;23(4):e267-e275. doi: 10.1111/hae.13220. Epub 2017 Jun 2. Haemophilia. 2017. PMID: 28574162

4

The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers.

MacEwan JP, Doctor J, Mulligan K, May SG, Batt K, Zacker C, Lakdawalla D, Goldman D. MacEwan JP, et al. Among authors: batt k. MDM Policy Pract. 2019 Jun 21;4(1):2381468319855386. doi: 10.1177/2381468319855386. eCollection 2019 Jan-Jun. MDM Policy Pract. 2019. PMID: 31259249 Free PMC article.

5

A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.

Batt K, Schultz BG, Caicedo J, Hollenbeak CS, Agrawal N, Chatterjee S, Bullano M. Batt K, et al. Curr Med Res Opin. 2022 Oct;38(10):1685-1693. doi: 10.1080/03007995.2022.2105072. Epub 2022 Aug 3. Curr Med Res Opin. 2022. PMID: 35880468 Free article.

6

Economic burden of multiple myeloma among patients in successive lines of therapy in the United States.

MacEwan JP, Batt K, Yin W, Peneva D, Sison S, Vine S, Chen C. MacEwan JP, et al. Among authors: batt k. Leuk Lymphoma. 2018 Apr;59(4):941-949. doi: 10.1080/10428194.2017.1361035. Epub 2017 Aug 13. Leuk Lymphoma. 2018. PMID: 28805105

7

The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.

Thornton Snider J, Batt K, Wu Y, Tebeka MG, Seabury S. Thornton Snider J, et al. Among authors: batt k. Am J Manag Care. 2017 Oct 1;23(10):e340-e346. Am J Manag Care. 2017. PMID: 29087638 Free article.

8

The well-being of long-term cancer survivors.

Sullivan J, Thornton Snider J, van Eijndhoven E, Okoro T, Batt K, DeLeire T. Sullivan J, et al. Among authors: batt k. Am J Manag Care. 2018 Apr;24(4):188-195. Am J Manag Care. 2018. PMID: 29668209 Free article.

9

The Option Value of Innovative Treatments for Metastatic Melanoma.

Thornton Snider J, Seabury S, Tebeka MG, Wu Y, Batt K. Thornton Snider J, et al. Among authors: batt k. Forum Health Econ Policy. 2018 Jun 21;21(1):/j/fhep.2018.21.issue-1/fhep-2016-0014/fhep-2016-0014.xml. doi: 10.1515/fhep-2016-0014. Forum Health Econ Policy. 2018. PMID: 30210050

10

The value of novel immuno-oncology treatments.

Romley JA, Delgado A, Shim J, Batt K. Romley JA, et al. Among authors: batt k. Am J Manag Care. 2018 Dec 1;24(12):e380-e385. Am J Manag Care. 2018. PMID: 30586486 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters